South Carolina COBRE in Oxidants, Redox Balance and Stress Signaling

项目总结 这一续展为我们的生物医学研究卓越中心寻求6-10年的支持 南卡罗来纳医科大学氧化剂、氧化还原平衡和压力信号研究(Cobre) (MUSC)。研究人员项目专注于人类病理，包括许多感知到的强项 包括癌症、心血管疾病、神经退行性疾病和药物/酒精成瘾以及 有药物发现和开发的其他组成部分。在每个实例中，它们的接口 具有氧化应激、氧化还原动态平衡和应激信号的疾病为 该中心的规划发展。我们计划通过5个项目的集群进一步开发这些资产 5个核心，涉及来自4个学科的10名知名科学家，项目主任来自4个 来自两所学院的不同系。由于需求的增加，在我们的选管会的要求下，我们有 在现有设施(蛋白质组学、细胞和分子)的基础上增加了一个新的核心(分析氧化还原) 成像、生物能量学分析、管理)。科布雷有许多教职员工 在1-4年级获得成功的助学金后毕业，其中大多数人仍然隶属于 程序。五个目标受试者的研究项目包括：对靶向蛋白酶体的药物的耐药性 多发性骨髓瘤，肿瘤干细胞生长的氧化还原调节，线粒体阴离子通道功能中的ROS， 主动脉瓣狭窄时线粒体功能中的ROS和迷走神经刺激中的抗氧化剂 帕金森氏症。辅导和职业发展努力也为维持 通过科布雷的科学成长和独立研究事业的发展。与上一次一样 随着初级教员取得成功，Cobre董事计划在 在未来五年内提供3到6名个人，为科布雷提供一支有资格的新调查人员队伍 程序。这个Cobre包括跨学院和跨部门的合作，董事们有 在医学和药学学院、霍林斯癌症中心和南卡罗来纳州的领导角色 治疗发现和发展中心。这包括招聘受赞助的主席， 可以作为导师和实验室空间参与药物发现大楼。在第一阶段，我们有 与来自南卡罗来纳大学(USC)和内布拉斯加州的科布雷合作，促进教学， 研究合作和技术专长。我们的第二阶段Cobre将继续强调 初级教员，以扩大和提高他们的研究计划。独立研究项目和提案， 氧化应激信号方面已建立的研究人员之间的强有力的互动，以及有效的指导 将继续是这次科布雷续约的压倒一切的目标。

Project summary This continuation renewal seeks support for years 6-10 for our Center of Biomedical Research Excellence (COBRE) in Oxidants, Redox Balance, and Stress Signaling at the Medical University of South Carolina (MUSC). Investigator projects focus on human pathologies that include many of the perceived strengths of MUSC including, cancer, cardiovascular disease, neurodegenerative disorders and drug/alcohol addiction and have additional components of drug discovery and development. In each instance the interface of these diseases with oxidant stress, redox homeostasis and stress signaling provides the fundamentals for the programmatic development of the Center. We plan to develop these assets further via clusters of 5 projects and 5 Cores involving 10 established scientists from 4 academic disciplines, with project Directors being from 4 different departments from 2 colleges. Because of increased demand and at the behest of our EAC, we have added a new core (Analytical Redox), in concert to the existing facilities (Proteomics, Cell and Molecular Imaging, Bioenergetics Profiling, Administrative). The COBRE has a number of faculty members who have graduated following successful grant awards garnered in years 1-4, most of whom remain affiliated with the program. Research projects for the five target mentees cover: resistance to drugs that target the proteasome in multiple myeloma, redox regulation of cancer stem cell growth, ROS in mitochondrial anion channel functions, ROS in mitochondrial function in aortic valve stenosis and antioxidants in vagus nerve stimulation in Parkinson's disease. Mentoring and career development efforts also provide critical mass in sustaining scientific growth and development of independent research careers through the COBRE. As with the previous period as junior faculty members achieve success, there are plans for the COBRE Directors to recruit between 3 and 6 individuals over the next five years, providing a cadre of new investigators eligible for the COBRE program. This COBRE includes cross-college and inter-department collaborations, with the Directors having leadership roles in the Colleges of Medicine and Pharmacy, the Hollings Cancer Center and South Carolina Center for Therapeutic Discovery and Development. This incorporates the recruitment of endowed chairs that can participate as mentors and laboratory space in the Drug Discovery Building. During Phase I, we have partnered with COBRE's from the University of South Carolina (USC) and Nebraska to foster teaching, research collaborations and technical expertise. Our Phase II COBRE will continue to emphasize the efforts of junior faculty, to expand and sharpen their research programs. Independent research projects and proposals, robust interactions among established investigators in oxidative stress signaling, along with effective mentoring will continue to be the overriding goals for this COBRE renewal.